# Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

> **NCT07537400** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shaare Zedek Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- High-Risk Neuroblastoma

## Interventions

- **DRUG:** Naxitamab

## Key facts

- **NCT ID:** NCT07537400
- **Lead sponsor:** Shaare Zedek Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-06
- **Final completion:** 2032-04
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07537400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07537400, "Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07537400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*